High rates of viral suppression in pregnancy drop postpartum in South African women on tenofovir‐lamivudine‐dolutegravir: a prospective cohort study
Journal of the International AIDS Society · 2025
DOI: 10.1002/jia2.70044 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the International AIDS Society, 2025. Verfasst von Elaine J Abrams und 7 weiteren Autor:innen. Beteiligte Einrichtung: ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Lamivudine, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), the National Institutes of Health.
Abstract (Originalsprache)
Introduction
Achieving and maintaining viral suppression (VS) during pregnancy and breastfeeding is central to preventing vertical transmission and optimizing maternal health. High rates of VS have been demonstrated among adult and paediatric populations receiving tenofovir‐lamivudine‐dolutegravir (TLD), but VS and viraemia among pregnant and postpartum women with HIV (WHIV) in high‐burden settings have not been well‐documented.
Methods
Between September 2021 and December 2023, pregnant WHIV, ≤18 weeks gestation, were enrolled in antenatal care (ANC) and followed postpartum in Cape Town, South Africa. WHIV received HIV care in routine health services and continued, switched to or initiated TLD at ANC entry. VS was defined as viral load (VL) 1000 copies/ml) or minor (50−1000 copies/ml). Mixed‐effects Poisson regression models were fit to assess factors associated with major VE risk.
Results
Among 763 WHIV with ≥1 VL, median age was 30 years (interquartile range [IQR] 25−34) and median gestation was 14 weeks at enrolment (IQR 11−17); 89% were on antiretroviral therapy, including 74% on TLD. Overall 99% achieved ≥1 VL
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, New York, USA.
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.
- Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.
- Department of Pediatrics and Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Division of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa.
ORCID-Profile: Elton Mukonda, Hlengiwe P Madlala, Allison Zerbe
Förderung
- Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
- the National Institutes of Health
Zitieren
APA
Abrams, E. J., Jao, J., Mukonda, E., Madlala, H. P., Matyseni, S., Zerbe, A., Legbedze, J., & Myer, L. (2025). High rates of viral suppression in pregnancy drop postpartum in South African women on tenofovir‐lamivudine‐dolutegravir: a prospective cohort study. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.70044
Vancouver
Abrams EJ, Jao J, Mukonda E, Madlala HP, Matyseni S, Zerbe A, et al. High rates of viral suppression in pregnancy drop postpartum in South African women on tenofovir‐lamivudine‐dolutegravir: a prospective cohort study. Journal of the International AIDS Society. 2025. doi:10.1002/jia2.70044
BibTeX
@article{Abrams2025,
author = {Abrams, Elaine J and Jao, Jennifer and Mukonda, Elton and Madlala, Hlengiwe P and Matyseni, Sandisiwe and Zerbe, Allison and Legbedze, Justine and Myer, Landon},
title = {High rates of viral suppression in pregnancy drop postpartum in South African women on tenofovir‐lamivudine‐dolutegravir: a prospective cohort study},
journal = {Journal of the International AIDS Society},
year = {2025},
doi = {10.1002/jia2.70044}
}
EUVIMED